Cover Image

Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity

Abstract Introduction Skin involvement in patients with psoriatic arthritis (PsA) worsens the severity and burden of disease. Ixekizumab (IXE), a selective interleukin (IL)-17A antagonist, was compared to placebo (PBO) in the SPIRIT-P1 (NCT01695239) and SPIRIT-P2 (NCT02349295) studies in patients wi...

Full description

Saved in:

Bibliographic Details
Main Authors:	April W. Armstrong (Author), Tarannum Jaleel (Author), Joseph F. Merola (Author), Alice B. Gottlieb (Author), Saakshi Khattri (Author), Cameron C. Helt (Author), William N. Malatestinic (Author), Sarah E. Ross (Author), Marcus E. Ngantcha (Author), Kurt de Vlam (Author)
Format:	Book
Published:	Adis, Springer Healthcare, 2024-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
by: April W. Armstrong, et al.
Published: (2024)

Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies
by: April Armstrong, et al.
Published: (2024)

Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection
by: Miller J, et al.
Published: (2021)

Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials
by: Joseph F. Merola, et al.
Published: (2024)

Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program
by: Alice B. Gottlieb, et al.
Published: (2023)

Ixekizumab-Associated Generalized Vitiligo and Pruritus in a Psoriatic Patient
by: Dayeon Jung, et al.
Published: (2024)

Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016-2021
by: Adam Reich, et al.
Published: (2023)

Consistent Efficacy of Apremilast in Patients with Psoriasis Regardless of Baseline Disease Severity or Special Area Involvement: Subgroup Analysis from PROMINENT
by: Masatoshi Abe, et al.
Published: (2024)

Ixekizumab
by: İlgen Ertam Sağduyu
Published: (2022)

Switching to ixekizumab improves adalimumab‐induced interstitial lung disease in patients with psoriatic arthritis: A case report
by: Hideki Hayashi, et al.
Published: (2021)

T cell epitope mapping of secukinumab and ixekizumab in healthy donors
by: Sebastian Spindeldreher, et al.
Published: (2020)

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Andrew Blauvelt, et al.
Published: (2023)

High HIV risk and syndemic burden regardless of referral source among MSM screening for a PrEP demonstration project in Toronto, Canada
by: James Wilton, et al.
Published: (2018)

Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials
by: Shawn G. Kwatra, et al.
Published: (2024)

INTERNATIONAL COOPERATION OF NNGASU - THE PROJECTS REGARDLESS OF TIME AND POLITICS
by: Yuriy V. Philippov
Published: (2016)

Prevalence of Musculoskeletal Symptoms in Patients with Psoriasis and Predictors Associated with the Development of Psoriatic Arthritis: Retrospective Analysis of a US Claims Database
by: Joseph F. Merola, et al.
Published: (2023)

Patient and Physician Perceptions of Psoriatic Disease in the United States: Results from the UPLIFT Survey
by: Joseph F. Merola, et al.
Published: (2023)

Apremilast as a treatment for morphea: A case series
by: Merav Koschitzky, BA, et al.
Published: (2022)

Ixekizumab‐induced urticarial drug eruption
by: Ayaka Kaneoka, et al.
Published: (2023)

Pyoderma gangrenosum in a patient on ixekizumab
by: Ilana R. Pollack, MSc, et al.
Published: (2021)

Erythrodermic psoriasis after discontinuation of ixekizumab
by: Kathryn Anne Potter, MD, et al.
Published: (2018)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Sekhon S, et al.
Published: (2017)

"Press on regardless!" - The role of volitional control in the first year of higher education
by: Caroline Trautwein, et al.
Published: (2015)

Social isolation, regardless of living alone, is associated with mortality: the Otassha study
by: Keigo Imamura, et al.
Published: (2024)

Neuroendocrine-immune relationships at rats regardless of sex and exposure to stressors or adaptogens
by: Oleksandr Plyska, et al.
Published: (2023)

Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial
by: Kristian Reich, et al.
Published: (2022)

Toxoplasmosis in a patient receiving ixekizumab for psoriasis
by: Yolanka Lobo, BPhysio, MBBS, et al.
Published: (2020)

Successful Treatment of Pityriasis Rubra Pilaris with Ixekizumab
by: Kathrin Hanfstingl, et al.
Published: (2018)

A Case of Ixekizumab-induced Psoriasiform Eruption
by: Tomohiro Oiwa, et al.
Published: (2019)

Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60
by: Alexander Egeberg, et al.
Published: (2024)

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis
by: Melissa A Michelon, et al.
Published: (2010)

Self-detected Melanomas are Thicker Regardless of Patient's Complexity: A Retrospective Analysis
by: Calogero Pagliarello, et al.
Published: (2023)

Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
by: Mark Lebwohl, et al.
Published: (2024)

Ixekizumab for the treatment of acrodermatitis continua of hallopeau and inverse psoriasis
by: Rui Yuan Xia, et al.
Published: (2023)

Successful treatment of rare linear lichen planopilaris with Ixekizumab
by: Hanof Ahmed, et al.
Published: (2023)

Generalized tinea versicolor following initiation of ixekizumab therapy
by: Haroon Sayed Alam, BS, et al.
Published: (2021)

The Successful Treatment of a Case of Linear Psoriasis with Ixekizumab
by: Sara Ghoneim, et al.
Published: (2017)

Tellurium-Doped Bioactive Glass Induces Ferroptosis in Osteosarcoma Cells Regardless of FSP1
by: Elżbieta Pańczyszyn, et al.
Published: (2024)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
by: Johansson E, et al.
Published: (2018)

Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States
by: Maryia Zhdanava, et al.
Published: (2024)